公开(公告)号：US20240075064A1

公开(公告)日：2024-03-07

申请号：US18261761

申请日：2022-01-18

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： Kutlu Goksu Elpek ,  Celeste Richardson ,  Michelle Lois Fleury ,  James Alex Storer ,  Shyamsundar Subramanian ,  Mithun Khattar

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/46444 ,  A61P35/00 ,  C07K14/5443 ,  C12N5/0636

摘要： The present disclosure provides compositions and methods for expanding T cells or tumor infiltrating lymphocytes (TILs) in vitro. K562 feeder cells engineered to express a costimulatory molecule (e.g., 41BB ligand (41BBL)) and either interleukin 21 (IL21) or interleukin 7 (IL7) can be used in a rapid expansion protocol (REP) step to expand the T cells or TILs. Thus, provided herein is a culture comprising T-cells or TILs and modified K562 feeder cells. The T cells can be modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) or the TILs can be modified to express membrane-bound IL15 (mbIL15). The T cells or TILs can be expanded in vitro using aREP without the use of exogenous interleukin 2 (IL2), and the expanded cells can be used in adoptive cell therapy for treatment of cancer without concomitant use of an exogenous cytokine such as IL2.

公开(公告)号：US20230092895A1

公开(公告)日：2023-03-23

申请号：US17753320

申请日：2019-08-30

申请人： Obsidian Therapeutics, Inc.

发明人： Vipin Suri ,  Michael Joseph Briskin ,  Brian Dolinski ,  Kutlu Goksu Elpek ,  Tucker Ezell ,  Scott Francis Heller ,  Mara Christine Inniss ,  Tariq A. Kassum ,  Nicole Kosmider ,  Abhishek Kulkarni ,  Meghan Langley ,  Dan Jun Li ,  Michelle Lynn Ols ,  Benjamin J. Primack ,  Celeste Richardson ,  Steven Mark Shamah ,  James Storer ,  Dexue Sun ,  Vijaya Balakrishnan ,  Andrew R.M. Bradbury ,  Michael Frank Erasmus ,  Fortunato Ferrara

IPC分类号： C12N9/06 ,  C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C07K14/725 ,  A61K35/17

摘要： The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

公开(公告)号：US11058725B2

公开(公告)日：2021-07-13

申请号：US17017670

申请日：2020-09-10

申请人： Obsidian Therapeutics, Inc.

发明人： Kutlu Goksu Elpek ,  Dhruv Kam Sethi ,  Meghan C. Langley ,  Tucker Read Ezell ,  Dexue Sun ,  Jennifer Leah Gori ,  Geetha Hanna Mylvaganam ,  Michelle Ols ,  Michelle Fleury ,  Celeste Richardson ,  James A. Storer ,  Vipin Suri ,  Shyamsundar Subramanian ,  Colleen Foley ,  Molly Reed Perkins ,  Jeremy Hatem Tchaicha ,  Scott Francis Heller

IPC分类号： A61K35/17 ,  C12N15/86 ,  C07K14/54 ,  A61K31/433 ,  C12N9/88 ,  C12N15/867 ,  C12N15/864 ,  C12N15/869 ,  C12N15/861

摘要： The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.